Surgery
Volume 28, Issue 3 , Pages 140-143 , March 2010

Adjuvant treatment for breast cancer

References 

  1. Cancer Research UK statistics. http://info.cancerresearchuk.org/cancerstats/types/breast/survival
  2. NICE clinical guideline 80. www.nice.org.uk/CG80
  3. Early Breast Cancer Trialists Collaborative Group (EBCTCG) . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  4. The START Trialists Group . The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107
  5. Hetelekidis S, Schnitt SJ, Silver B, et al. The significance of extracapsular extension of axillary lymph node metastases in early breast cancer. Int J Radiat Oncol Biol Phys. 2000;46:31–34
  6. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol. 2007;82:265–271
  7. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410
  8. EBCTCG . Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  9. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen alone or in combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  10. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med. 2004;350:1081–1092
  11. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with hormonal responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  12. Goss PE, Inge J, Martino S, et al. Randomized trial of letrazole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  13. Piccart-Gebhart , et al. Transtuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  14. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab treated patients with breast cancer: updated United Kingdom National Cancer Research Institute Recommendations for monitoring. Br J Cancer. 2009;100:684–692
  15. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy for breast cancer. Ann Oncol. 2005;16:1569–1583

PII: S0263-9319(09)00278-6

doi: 10.1016/j.mpsur.2009.11.002

Surgery
Volume 28, Issue 3 , Pages 140-143 , March 2010

Article Tools

* Image Usage & Resolution